What Does a High Arachidonic Acid to EPA Ratio Mean?

What Is the AA/EPA Ratio?

The arachidonic acid to EPA ratio (AA/EPA ratio) is one of the most clinically meaningful^[1] markers of systemic inflammatory status available , yet it appears in very few standard lab panels. At The Lamkin Clinic, we consider it an essential component of cardiovascular, cognitive, and metabolic risk assessment. Understanding what a high AA/EPA ratio means, and what to do about it, can have profound implications for long-term health outcomes.

The Biochemistry of AA and EPA

Arachidonic acid (AA) is a 20-carbon omega-6 polyunsaturated fatty acid^[3] derived primarily from grain-fed meats, eggs, and the enzymatic elongation of linoleic acid (the dominant fatty acid in processed vegetable oils). It serves as the primary substrate for pro-inflammatory eicosanoids: prostaglandins of the 2-series, thromboxane A2, and leukotrienes of the 4-series, signaling molecules that drive vascular inflammation, platelet aggregation, and immune activation. EPA (eicosapentaenoic acid) is a 20-carbon omega-3 fatty acid found in cold-water fatty fish and fish oil. It competes directly with AA for the same enzymatic pathways, producing anti-inflammatory eicosanoids of the 3-series and 5-series that resolve inflammation, promote vasodilation, and reduce platelet stickiness. The ratio between these two fatty acids in cell membranes, the AA/EPA ratio, determines which direction the inflammatory balance tips.

What the Numbers Mean

Reference ranges for the AA/EPA ratio vary significantly^[1] across populations based on dietary patterns. In Japan, where marine-derived omega-3 consumption is high, population AA/EPA ratios average approximately 1.5:1, and Japanese populations have correspondingly low rates of cardiovascular disease, inflammatory conditions, and cognitive decline. In the United States, the average AA/EPA ratio is 15:1 to 25:1, reflecting a diet dominated by omega-6-rich seed oils and low in marine omega-3s. Optimal AA/EPA ratio for anti-inflammatory protection is generally considered below 6:1, with optimal values ideally in the 2:1 to 4:1 range.

Clinical Consequences of a High AA/EPA Ratio

An elevated AA/EPA ratio has been associated in clinical research^[2][5] with significantly increased cardiovascular disease risk, including increased risk of myocardial infarction and stroke; elevated hs-CRP and systemic inflammation independent of standard lipid markers; depression and anxiety, as omega-3 fatty acids are critical for serotonin receptor function and neuronal membrane fluidity; cognitive decline and Alzheimer's disease risk; insulin resistance and impaired glucose metabolism; autoimmune disease activity and flares; and poor healing and recovery from injury. What makes the AA/EPA ratio particularly valuable is that it can be significantly elevated while standard inflammatory markers like hs-CRP remain within normal limits, making it a window into chronic low-grade inflammation that other tests miss.

Dietary Drivers and How to Correct Them

The primary dietary driver of elevated AA/EPA ratio^[4] is the dramatic increase in omega-6 linoleic acid consumption through refined seed oils: corn oil, soybean oil, sunflower oil, safflower oil, and canola oil. These oils now constitute the dominant fat source in the American diet and are ubiquitous in processed foods, restaurant cooking, and fast food. Simultaneously, consumption of marine-derived omega-3s has declined. The result is a dietary omega-6 to omega-3 ratio of approximately 15:1 to 20:1, compared to the estimated ancestral ratio of 1:1 to 4:1 for which human metabolism was optimized.

Omega-3 Supplementation: Dose Matters

Effective correction requires both reducing omega-6 intake^[3] and increasing EPA. Eliminating or dramatically reducing refined seed oils, replacing them with olive oil, avocado oil, butter, and coconut oil , is the most impactful dietary change. Increasing consumption of wild-caught fatty fish (salmon, sardines, mackerel, anchovies) provides direct EPA and DHA. However, dietary change alone is rarely sufficient to achieve therapeutic AA/EPA ratios in patients with significant baseline elevation. High-quality omega-3 supplementation at 3,000, 5,000 mg/day of combined EPA+DHA, with emphasis on EPA-dominant formulations in triglyceride form (superior bioavailability over ethyl ester), is typically necessary. We re-test the omega-3 index at 90-day intervals to verify therapeutic target achievement.

The Lamkin Clinic, Edmond Oklahoma | lamkinclinic.com

References and Further Reading

1. [1]Simopoulos AP. The omega-6/omega-3 ratio and cardiovascular and other chronic diseases. Exp Biol Med. 2008;233(6):674-688.
2. [2]Harris WS, et al. Omega-3 fatty acids and coronary heart disease risk. Atherosclerosis. 2008;197(1):12-24.
3. [3]Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2(3):355-374.
4. [4]Blasbalg TL, et al. Changes in consumption of omega-3 and omega-6 fatty acids in the United States. Am J Clin Nutr. 2011;93(5):950-962.
5. [5]Kris-Etherton PM, et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-2757.